Amgen Inc. (AMGN)
Largest Insider Buys in Sector
AMGN Stock Price History Chart
AMGN Stock Performance
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Insider Activity of Amgen Inc.
Over the last 12 months, insiders at Amgen Inc. have bought $0 and sold $662,802 worth of Amgen Inc. stock.
On average, over the past 5 years, insiders at Amgen Inc. have bought $0 and sold $5.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,020 shares for transaction amount of $1M was made by Hassan Fred (director) on 2015‑08‑19.
List of Insider Buy and Sell Transactions, Amgen Inc.
| 2024-05-03 | Sale | SVP & CCO | 2,117 0.0004% | $313.09 | $662,802 | +2.47% | ||
| 2023-12-04 | Sale | SVP & CCO | 2,096 0.0004% | $273.03 | $572,276 | +11.78% | ||
| 2023-11-08 | Sale | EVP, Gen. Counsel & Secy. | 10,000 0.0019% | $272.81 | $2.73M | +11.12% | ||
| 2023-08-10 | Sale | EVP, Global Commercial Ops | 9,558 0.0018% | $262.43 | $2.51M | +5.68% | ||
| 2022-11-09 | Sale | SVP, Business Development | 387 <0.0001% | $292.90 | $113,352 | -11.93% | ||
| 2022-11-08 | Sale | SVP & CCO | 545 0.0001% | $293.54 | $159,977 | -12.76% | ||
| 2022-08-22 | Sale | 200 <0.0001% | $249.96 | $49,992 | -1.11% | |||
| 2022-08-18 | Sale | 6,600 0.0012% | $249.00 | $1.64M | -2.22% | |||
| 2022-05-23 | Sale | 1,200 0.0002% | $250.00 | $300,000 | -0.65% | |||
| 2022-05-10 | Sale | EVP, Gen. Counsel & Secy. | 27,000 0.0051% | $241.81 | $6.53M | +3.63% | ||
| 2021-05-12 | Sale | director | 2,000 0.0002% | $161.12 | $322,230 | -6.81% | ||
| 2021-05-11 | Sale | SVP & CCO | 5,000 0.0007% | $207.55 | $1.04M | -7.35% | ||
| 2021-05-07 | Sale | director | 500 <0.0001% | $251.78 | $125,890 | -8.09% | ||
| 2021-04-14 | Sale | director | 2,000 0.0002% | $160.81 | $321,620 | -6.30% | ||
| 2021-03-10 | Sale | director | 2,000 0.0002% | $151.59 | $303,170 | +1.39% | ||
| 2021-02-10 | Sale | director | 2,000 0.0002% | $155.02 | $310,040 | -1.80% | ||
| 2021-02-08 | Sale | director | 500 <0.0001% | $119.00 | $59,498 | -1.43% | ||
| 2021-02-04 | Sale | EVP, Gen. Counsel & Secy. | 22,220 0.0038% | $236.51 | $5.26M | -1.28% | ||
| 2021-01-13 | Sale | director | 2,000 0.0002% | $118.00 | $235,990 | -0.60% | ||
| 2020-11-09 | Sale | director | 500 <0.0001% | $121.20 | $60,600 | +1.39% |
Insider Historical Profitability
| Grygiel Nancy A. | SVP & CCO | 9883 0.0018% | $278.42 | 0 | 4 | |
| JOHNSON FRANKLIN P JR | director | 1636961 0.3045% | $278.42 | 0 | 15 | |
| Bradway Robert A | Chairman, CEO and President | 383102 0.0713% | $278.42 | 1 | 2 | +39.22% |
| FRITZKY EDWARD V | director | 231000 0.043% | $278.42 | 0 | 8 | |
| PERLMUTTER ROGER M | EVP, Research & Development | 186031 0.0346% | $278.42 | 0 | 6 | |
| OMENN GILBERT S | director | 176783 0.0329% | $278.42 | 0 | 7 | |
| LAZARUS STEVEN | director | 149343 0.0278% | $278.42 | 0 | 5 | |
| FENTON DENNIS M | Executive V.P., Operations | 117518 0.0219% | $278.42 | 0 | 20 | |
| MORROW GEORGE J | Exe VP, Global Commercial Ops | 93719 0.0174% | $278.42 | 1 | 4 | <0.0001% |
| ODRE STEVEN M | Sr. VP, Gen. Counsel & Secy. | 76705 0.0143% | $278.42 | 0 | 2 | |
| SCOTT DAVID J | SVP, Gen. Counsel & Secy. | 65558 0.0122% | $278.42 | 0 | 4 | |
| Harper Sean E | EVP, Research & Development | 56082 0.0104% | $278.42 | 0 | 15 | |
| Balachandran Madhavan | EVP, Operations | 55996 0.0104% | $278.42 | 0 | 4 | |
| MCNAMEE BRIAN M | EVP | 54643 0.0102% | $278.42 | 0 | 19 | |
| Meline David W | EVP & CFO | 49378 0.0092% | $278.42 | 0 | 1 | |
| CHOATE JERRY D | director | 48575 0.009% | $278.42 | 1 | 2 | <0.0001% |
| BONANNI FABRIZIO | EVP, Operations | 48491 0.009% | $278.42 | 0 | 13 | |
| Gordon Murdo | EVP, Global Commercial Ops | 44308 0.0082% | $278.42 | 0 | 1 | |
| Flanagan Thomas James | Sr VP & CIO | 41826 0.0078% | $278.42 | 0 | 4 | |
| Michael A Kelly | Acting CFO | 41041 0.0076% | $278.42 | 0 | 6 | |
| Piacquad David | SVP, Business Development | 39700 0.0074% | $278.42 | 0 | 1 | |
| BEIER DAVID W | SVP, Global Govt Affairs | 35612 0.0066% | $278.42 | 0 | 7 | |
| BALTIMORE DAVID | director | 31159 0.0058% | $278.42 | 0 | 8 | |
| BIONDI FRANK | director | 29780 0.0055% | $278.42 | 0 | 4 | |
| Graham Jonathan P | EVP, Gen. Counsel & Secy. | 28078 0.0052% | $278.42 | 0 | 4 | |
| REASON J PAUL | director | 23591 0.0044% | $278.42 | 0 | 2 | |
| MILETICH JOSEPH P | Sr VP Rsch & Preclinical Dev | 22500 0.0042% | $278.42 | 0 | 1 | |
| Patton Cynthia M | SVP & CCO | 22097 0.0041% | $278.42 | 0 | 6 | |
| Tross Stuart A | SVP, Human Resources | 21923 0.0041% | $278.42 | 0 | 2 | |
| ECKERT ROBERT | 21184 0.0039% | $278.42 | 0 | 1 | ||
| Dittrich Thomas J.W. | VP, Finance & CAO | 18589 0.0035% | $278.42 | 0 | 5 | |
| SCHAEFFER LEONARD D | director | 16329 0.003% | $278.42 | 0 | 2 | |
| SUGAR RONALD D | director | 15927 0.003% | $278.42 | 0 | 20 | |
| GLUCK FREDERICK W | director | 15748 0.0029% | $278.42 | 1 | 3 | <0.0001% |
| de Carbonnel Francois | director | 15528 0.0029% | $278.42 | 2 | 4 | +16.13% |
| PELHAM JUDITH C | director | 11890 0.0022% | $278.42 | 0 | 9 | |
| COFFMAN VANCE D | director | 10668 0.002% | $278.42 | 1 | 0 | <0.0001% |
| NANULA RICHARD D | Exe VP & CFO | 10000 0.0019% | $278.42 | 0 | 6 | |
| RICHO ANNA | SVP & CCO | 10256 0.0019% | $278.42 | 0 | 12 | |
| Jacks Tyler | director | 8979 0.0017% | $278.42 | 0 | 1 | |
| Such Annette Louise | VP, Finance and CAO | 7183 0.0013% | $278.42 | 0 | 1 | |
| Khosla Rachna | SVP, Business Development | 6630 0.0012% | $278.42 | 0 | 1 | |
| SHARER KEVIN W | director | 5494 0.001% | $278.42 | 0 | 15 | |
| HENDERSON REBECCA M | director | 5549 0.001% | $278.42 | 0 | 2 | |
| Williams R Sanders | 5301 0.001% | $278.42 | 0 | 10 | ||
| Hassan Fred | director | 3582 0.0007% | $278.42 | 1 | 0 | <0.0001% |
| HERRINGER FRANK C | director | 2000 0.0004% | $278.42 | 2 | 0 | +3.73% |
| DAYEM HASSAN | Sr. V.P. & Chief Info. Officer | 1349 0.0003% | $278.42 | 0 | 2 | |
| SCHEHR BARRY D | VP Financial Ops & CAO | 0 0% | $278.42 | 0 | 3 |
Institutional Investor Ownership
| The Vanguard Group | $14.81B | 9.71 | 52.09M | +6.21% | +$865.94M | 0.27 | |
| BlackRock | $13.64B | 8.94 | 47.97M | +0.33% | +$45.12M | 0.3 | |
| State Street | $8.28B | 5.43 | 29.13M | -1.13% | -$94.3M | 0.34 | |
| PRIMECAP Management Co | $4.15B | 2.72 | 14.6M | +0.07% | +$2.98M | 3.05 | |
| Morgan Stanley | $3.97B | 2.61 | 13.97M | -3.2% | -$131.38M | 0.29 | |
| Geode Capital Management | $3.3B | 2.17 | 11.64M | -5.64% | -$197.61M | 0.28 | |
| Charles Schwab | $3.08B | 2.02 | 10.83M | +4.23% | +$124.88M | 0.67 | |
| Wells Fargo | $2.13B | 1.4 | 7.5M | +0.19% | +$3.95M | 0.57 | |
| Capital International Investors | $1.99B | 1.31 | 7.01M | +547.82% | +$1.68B | 0.4 | |
| Northern Trust | $1.71B | 1.12 | 6.02M | -6.18% | -$112.7M | 0.28 | |
| Capital Research Global Investors | $1.61B | 1.06 | 5.67M | -15.45% | -$294.52M | 0.37 | |
| Royal Bank of Canada | $1.55B | 1.02 | 5.46M | -6.37% | -$105.61M | 0.37 | |
| BNY Mellon | $1.52B | 1 | 5.36M | -2.43% | -$37.91M | 0.29 | |
| Legal & General | $1.41B | 0.93 | 4.97M | -0.99% | -$14.16M | 0.33 | |
| Barclays | $1.23B | 0.81 | 4.34M | +48.91% | +$405.56M | 0.56 | |
| Goldman Sachs | $1.22B | 0.8 | 4.3M | +11.73% | +$128.46M | 0.23 | |
| Aristotle | $1.15B | 0.75 | 4.04M | -2.67% | -$31.49M | 2.2 | |
| Fidelity Investments | $1.14B | 0.75 | 4.02M | -15.87% | -$215.38M | 0.08 | |
| UBS | $1.07B | 0.7 | 3.75M | +11.52% | +$110.06M | 0.32 | |
| JPMorgan Chase | $1.02B | 0.67 | 3.57M | -9.91% | -$111.69M | 0.09 | |
| Nuveen | $990.96M | 0.65 | 3.49M | -2.33% | -$23.59M | 0.28 | |
| Ubs Asset Management Americas Inc | $957.17M | 0.63 | 3.37M | -7.03% | -$72.39M | 0.34 | |
| Amundi | $885.05M | 0.63 | 3.37M | +11.21% | +$89.21M | 0.37 | |
| Bank of America | $946.15M | 0.62 | 3.33M | -21.9% | -$265.28M | 0.09 | |
| Deutsche Bank | $926.78M | 0.61 | 3.26M | +17.34% | +$136.92M | 0.42 | |
| T. Rowe Price | $892.05M | 0.59 | 3.14M | -52.21% | -$974.43M | 0.11 | |
| Invesco | $880.4M | 0.58 | 3.1M | -11.14% | -$110.41M | 0.18 | |
| CalPERS | $782.54M | 0.51 | 2.75M | +1.33% | +$10.3M | 0.55 | |
| State Farm | $772.12M | 0.51 | 2.72M | 0% | +$0 | 0.7 | |
| Dimensional Fund Advisors | $722M | 0.47 | 2.54M | +2.53% | +$17.81M | 0.19 | |
| Janus Henderson | $676.98M | 0.44 | 2.38M | +137.13% | +$391.5M | 0.34 | |
| Boston Partners | $635.18M | 0.42 | 2.24M | +27.4% | +$136.62M | 0.75 | |
| Ameriprise Financial | $561.15M | 0.37 | 1.97M | -8.87% | -$54.65M | 0.16 | |
| AllianceBernstein | $555.34M | 0.36 | 1.95M | -5.17% | -$30.29M | 0.2 | |
| Montrusco Bolton Investments Inc | $501.76M | 0.34 | 1.81M | +60.65% | +$189.43M | 5.37 | |
| Nordea Investment Management Ab | $515.23M | 0.34 | 1.8M | -0.02% | -$86,182.32 | 0.61 | |
| Franklin Templeton Investments | $480.59M | 0.32 | 1.69M | +4.01% | +$18.51M | 0.14 | |
| HSBC | $478.06M | 0.31 | 1.68M | +14.55% | +$60.72M | 0.34 | |
| Sumitomo Mitsui Trust Holdings | $471.98M | 0.31 | 1.66M | +0.19% | +$889,068.64 | 0.32 | |
| Swiss National Bank | $455.69M | 0.3 | 1.6M | -4.18% | -$19.9M | 0.3 | |
| Beutel, Goodman & Company Ltd. | $452.43M | 0.3 | 1.59M | +1.38% | +$6.14M | 2.33 | |
| Federated Hermes | $418.5M | 0.27 | 1.47M | -15.34% | -$75.85M | 0.97 | |
| Stifel | $407.51M | 0.27 | 1.43M | +5.52% | +$21.31M | 0.47 | |
| LSV Asset Management | $386.71M | 0.25 | 1.36M | -25.68% | -$133.66M | 0.8 | |
| Allianz Asset Management Gmbh | $383.78M | 0.25 | 1.35M | +5.76% | +$20.92M | 0.65 | |
| Envestnet Asset Management Inc | $370.09M | 0.24 | 1.3M | +7.37% | +$25.4M | 0.14 | |
| Bank of Montreal | $350.08M | 0.23 | 1.22M | -32.16% | -$166M | 0.11 | |
| Sarasin & Partners LLP | $324.52M | 0.21 | 1.14M | -0.55% | -$1.79M | 3.2 | |
| Credit Suisse | $311.64M | 0.2 | 1.1M | -5.08% | -$16.69M | 0.29 | |
| PNC Financial Services | $307.43M | 0.2 | 1.08M | -1.86% | -$5.83M | 0.22 |